Members of a US Food and Drug Administration advisory panel, to a person, concluded that the potential benefits of OTC sales of a daily oral contraceptive outweigh the risks.
Several agreed with FDA concerns about some data the sponsor of the application for the OTC switch provided, but a larger number noted the historic nature of HRA Pharma’s proposal and of their two-day